KROS – keros therapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
Keros Therapeutics (KROS) had its price target lowered by Wells Fargo & Company from $23.00 to $20.00. They now have an "overweight" rating on the stock.
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Keros Therapeutics Appoints Charles Newton to its Board of Directors
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Keros Therapeutics (NASDAQ:KROS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Form 8-K Keros Therapeutics, Inc. For: Mar 04
Form S-8 Keros Therapeutics, Inc.
Form 10-K Keros Therapeutics, Inc. For: Dec 31
Form 8-K Keros Therapeutics, Inc. For: Mar 04
Form 4 Keros Therapeutics, Inc. For: Feb 24 Filed by: Lerner Lorena Raquel
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.